Study to Evaluate Safety, Reactogenicity and Immunogenicity of the Pneumococcal Protein PhtD Vaccine in Healthy Adults

NCT01767402 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Pneumococcal Disease

Interventions

BIOLOGICAL: PhtD vaccine with/without adjuvant
BIOLOGICAL: Pneumovax 23TM
BIOLOGICAL: NaCl

Sponsor

GlaxoSmithKline